Clinical Trials
15 trialsNCT06141070 2026-04-14
ANDROMEDA
Vastra Gotaland Region
Phase 3 Recruiting
NCT05236946 2025-09-10
Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT
Tata Memorial Hospital
Phase 3 Recruiting
NCT05278052 2025-09-10
TARGET-02
Tata Memorial Hospital
Phase 3 Recruiting
NCT07050043 2025-07-03
LEDANG
Hospital Sultanah Bahiyah
Phase 3 Recruiting
NCT02455843 2017-09-19
Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC
Shandong Provincial Hospital
Phase 3 Unknown
NCT02896166 2017-06-14
Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer
Shandong Provincial Hospital
Phase 3 Unknown
NCT03008109 2017-01-04
Endostar Plus EGFR-TKI(Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor) as a Treatment of EGFR Mutation-positive NSCLC
Air Force General Hospital of the PLA
Phase 3 Unknown
NCT02738346 2016-04-25
CBPC
University Hospital, Angers
Phase 3 Unknown
NCT00864331 2013-08-07
Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy
International Atomic Energy Agency
Phase 3 Completed
NCT00821860 2013-06-28
MesoVATS
Papworth Hospital NHS Foundation Trust
Phase 3 Completed
NCT01836575 2013-04-22
PS2
Instituto Nacional de Cancer, Brazil
Phase 3 Completed
NCT00455936 2010-10-25
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
National Cancer Center, Korea
Phase 3 Completed
NCT00576914 2010-03-09
Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
Chinese Academy of Sciences
Phase 3 Unknown
NCT01041833 2010-01-01
Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and Expression of RAR-alfa and RAR-beta as Response Biomarker
National Institute of Cancerología
Phase 3 Unknown
NCT00268684 2006-02-28
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
Tel-Aviv Sourasky Medical Center
Phase 3 Unknown